Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology.
Animals
COVID-19
/ metabolism
Chlorocebus aethiops
Chromatography, Liquid
/ methods
Dioxanes
/ pharmacology
Disease Models, Animal
Gangliosides
/ blood
Glucosyltransferases
/ antagonists & inhibitors
Humans
Mass Spectrometry
/ methods
Mice, Transgenic
Pyrrolidines
/ pharmacology
SARS-CoV-2
/ drug effects
Sphingolipids
/ blood
Sphingosine
/ analogs & derivatives
Vero Cells
Virus Replication
/ drug effects
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
23
07
2021
revised:
25
10
2021
accepted:
26
10
2021
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
27
11
2021
Statut:
epublish
Résumé
Understanding pathways that might impact coronavirus disease 2019 (COVID-19) manifestations and disease outcomes is necessary for better disease management and for therapeutic development. Here, we analyzed alterations in sphingolipid (SL) levels upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection induced elevation of SL levels in both cells and sera of infected mice. A significant increase in glycosphingolipid levels was induced early post SARS-CoV-2 infection, which was essential for viral replication. This elevation could be reversed by treatment with glucosylceramide synthase inhibitors. Levels of sphinganine, sphingosine, GA1, and GM3 were significantly increased in both cells and the murine model upon SARS-CoV-2 infection. The potential involvement of SLs in COVID-19 pathology is discussed.
Identifiants
pubmed: 34764206
pii: 5/1/e202101168
doi: 10.26508/lsa.202101168
pmc: PMC8605327
pii:
doi:
Substances chimiques
(2-(2',3'-dihydrobenzo(1,4)dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethylethyl)nonanoic acid amide
0
Dioxanes
0
Gangliosides
0
Pyrrolidines
0
Sphingolipids
0
Glucosyltransferases
EC 2.4.1.-
ceramide glucosyltransferase
EC 2.4.1.80
Sphingosine
NGZ37HRE42
safingol
OWA98U788S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 Vitner et al.
Références
Lipids Health Dis. 2015 Jun 16;14:55
pubmed: 26076974
Sci Rep. 2021 Jul 9;11(1):14232
pubmed: 34244584
Front Cell Dev Biol. 2021 Jun 17;9:689854
pubmed: 34222257
Acta Neuropathol Commun. 2020 Aug 24;8(1):144
pubmed: 32831144
Toxicol Appl Pharmacol. 1993 Jan;118(1):105-12
pubmed: 8430417
Nature. 2021 Jan;589(7840):125-130
pubmed: 32906143
FEBS J. 2013 Dec;280(24):6338-53
pubmed: 24165035
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Circulation. 2004 Nov 30;110(22):3465-71
pubmed: 15545514
Fundam Appl Toxicol. 1996 Jun;31(2):169-72
pubmed: 8789782
Lancet. 2020 Jun 6;395(10239):1741-1743
pubmed: 32410759
Biol Chem. 2018 Sep 25;399(10):1115-1123
pubmed: 29975662
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Brain Behav Immun Health. 2021 Mar;12:100203
pubmed: 33462567
J Biol Chem. 2005 Mar 18;280(11):10284-9
pubmed: 15590644
Cell Mol Life Sci. 2013 Jan;70(2):181-203
pubmed: 22729185
J Cell Sci. 2019 Jul 31;132(15):
pubmed: 31371572
Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2561-6
pubmed: 15699349
Front Neurosci. 2020 Oct 06;14:572965
pubmed: 33117120
Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17345-50
pubmed: 20855599
Hepatology. 2008 Nov;48(5):1396-403
pubmed: 18830996
PLoS Pathog. 2012;8(3):e1002584
pubmed: 22457619
PLoS Pathog. 2018 Feb 15;14(2):e1006853
pubmed: 29447265
Front Neurol. 2020 May 21;11:437
pubmed: 32528400
PLoS Pathog. 2010 Jan;6(1):e1000719
pubmed: 20062526
Cell Rep Med. 2020 Nov 17;1(8):100142
pubmed: 33163980
Biochem Pharmacol. 2007 May 1;73(9):1340-6
pubmed: 17239824
Essays Biochem. 2020 Sep 23;64(3):579-589
pubmed: 32579188
J Oleo Sci. 2011;60(10):537-44
pubmed: 21937853
Viruses. 2019 Oct 01;11(10):
pubmed: 31581580
J Neurol Sci. 2020 Oct 15;417:117085
pubmed: 32871412
J Biochem. 1984 Mar;95(3):761-70
pubmed: 6725233
J Biol Chem. 2021 Jan-Jun;296:100470
pubmed: 33639165
Toxicol Appl Pharmacol. 2000 Feb 1;162(3):151-60
pubmed: 10652243
Int J Mol Sci. 2021 Apr 15;22(8):
pubmed: 33920904
Biol Chem. 2015 Jun;396(6-7):585-95
pubmed: 25525752
J Biol Chem. 2008 Sep 19;283(38):26148-60
pubmed: 18644793
Lipids Health Dis. 2019 Jan 25;18(1):26
pubmed: 30683111
J Virol. 2004 Apr;78(8):4197-206
pubmed: 15047835
Atherosclerosis. 2013 Jan;226(1):16-28
pubmed: 23075523
Handb Exp Pharmacol. 2013;(216):321-40
pubmed: 23563664
Nature. 2014 Jun 5;510(7503):68-75
pubmed: 24899306
Virol J. 2017 Feb 13;14(1):28
pubmed: 28193229
FEBS Lett. 2020 Nov;594(22):3619-3631
pubmed: 33131047
Diabetes. 2007 May;56(5):1210-8
pubmed: 17470562
Tohoku J Exp Med. 2015;237(2):133-40
pubmed: 26447086
J Virol. 2013 May;87(9):4994-5004
pubmed: 23427160
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
Adv Clin Exp Med. 2021 Jan;30(1):101-107
pubmed: 33529513
Am J Vet Res. 1999 Oct;60(10):1292-300
pubmed: 10791944
Cell Mol Immunol. 2020 May;17(5):555-557
pubmed: 32235915
Biochim Biophys Acta. 2006 Dec;1758(12):1864-84
pubmed: 17052686
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
Curr Neurol Neurosci Rep. 2021 Feb 14;21(3):9
pubmed: 33586020
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910